Bristol-Myers and Pfizer collaborate on Eliquis study with Portola's universal Factor Xa inhibitor antidote PRT4445

Portola Pharmaceuticals, Bristol-Myers Squibb  (NYSE: BMY) and Pfizer (NYSE: PFE) last week announced a clinical collaboration to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor Eliquis (apixaban). PRT4445 is a universal Factor Xa inhibitor antidote in clinical development designed to reverse the anticoagulant activity of any Factor Xa inhibitor. No agents are approved to reverse the activity of Factor Xa inhibitors.

The collaboration will be in effect during the clinical proof-of-concept study, which is anticipated to start by the end of this year. The study is designed to demonstrate the safety of PRT4445 and its ability to reverse the anticoagulation activity of Eliquis and other Factor Xa inhibitors, including betrixaban, Portola’s Phase III oral Factor Xa inhibitor. B-MS and Pfizer will make an undisclosed cash payment to Portola on initiation of the proof-of-concept study with Eliquis and will provide development and regulatory guidance for the

Need for antidote to help manage infrequent but serious bleeding events